Paclitaxel for Breast Cancer: 167 Real Stories

167 stories match breast cancer and paclitaxel. 151 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

HER2-positive apocrine breast cancer: chemotherapy and Herceptin

Patient Info: Anonymized, Female, 60s

Biomarkers: HER2-positive; AR-positive; ER-negative; PR-negative

Disease-free for 2 years after treatment for HER2-positive apocrine breast cancer, with no reported lymph-node recurrence or distant metastases during surveillance.

PubMed Central
OutcomeCancer-Free / NED
Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast carcinoma to pancreas: biliary stent and paclitaxel

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary breast tumor was triple-negative. Pancreatic metastasis was ER-positive/GATA-positive

Metastatic Site: pancreas; coelio-mesenteric lymph nodes

After 21 years of remission, she developed pancreatic and coelio-mesenteric nodal metastases from invasive lobular breast carcinoma; palliative paclitaxel was stopped after 2 courses because her condition deteriorated, and she was lost to follow-up.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

BRCA2-Positive Breast Cancer in a Woman With Down Syndrome

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative, germline BRCA2 pathogenic variant

Metastatic Site: lungs, bones

The cancer later progressed with lung and bone metastases and extensive cancer spread through lymphatic vessels in both lungs. She died 59 months after breast surgery.

PubMed Central
OutcomeIn Memory
Chantal, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Chantal's Survivor Story

Patient Info: Chantal, Female, Under 40 | Stage II

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of December 2023, Chantal reported that she did not currently have cancer, was followed by medical oncology every 3-4 months, and used Signatera testing because tumor markers were not reliable for her.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Mucoepidermoid Breast Cancer With 61 Months Without Recurrence

Patient Info: Anonymized, female, 50s

Biomarkers: HER2-positive; ER low expression; PR-negative

She was alive without signs of recurrence after 61 months of follow-up, providing just over 5 years of documented follow-up for this second primary breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed Central
OutcomeIn Memory
Kelly, who was diagnosed with Stage III Breast CancerBreast Cancer

Kelly's Stage 3 Breast Cancer Story: “I’m Still Here & THRIVING!"

Patient Info: Kelly Thomas, Female, Under 40 | Stage III

Biomarkers: Initial triple-negative breast cancer; after surgery

As of August 2023, Kelly was 5 years from her Stage IIIC triple-negative breast cancer diagnosis with no recurrence reported.

The Patient Story
OutcomeCancer-Free / NED
Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Megan-Claire, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II Invasive Lobular Carcinoma: Megan-Claire's Survivor Story

Patient Info: Megan-Claire, Female, Under 40 | Stage II

As of July 2023, Megan-Claire had completed chemotherapy, breast-conserving surgery with reconstruction/reduction, and 33 radiation rounds, and was living with long-term effects including neuropathy, scarring, fatigue, and radiation trauma; no recurrence or NED status was stated.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Lucinda, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Lucinda's Patient Story

Patient Info: Lucinda Rudolph, Female, 60s

As of June 2023, Lucinda was living well after treatment for locally advanced recurrent invasive lobular breast cancer, taking exemestane, receiving supportive care for neuropathy, and returning to MD Anderson every 6 months for checkups.

MD Anderson
OutcomeCare Ongoing
Carol, who was diagnosed with Breast CancerBreast Cancer

BRCA1 Breast Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart

Biomarkers: BRCA1 mutation

She had a complete pathologic response to breast chemotherapy and later reported no evidence of breast cancer.

MD Anderson
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Elliott, Female, Under 40 | Stage III

Biomarkers: Estrogen receptor-positive; HER2 and progesterone receptor status not reported

As of May 2023, Christine was about 3 years from diagnosis and in survivorship after chemotherapy, lumpectomy, and radiation. She reported lasting physical and emotional effects but did not state a formal NED status.

YouTube — The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare breast blood-vessel cancer (angiosarcoma) in a teenage girl

Patient Info: Anonymized, Female

Biomarkers: Testing for Li-Fraumeni syndrome and POT1 mutation was inconclusive; no inherited cancer predisposition was established

She remained in remission 3 years after diagnosis and continued annual MRI surveillance of the reconstructed and opposite breasts.

PubMed Central
OutcomeCancer-Free / NED
Lucy, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy E., Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

As of January 2023, Lucy had been told she was all-clear/cancer-free after chemotherapy, had undergone double mastectomy with staged reconstruction planning, and was continuing close oncology reviews every 3-4 months.

The Patient Story
OutcomeCancer-Free / NED
Anne, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Anne's Patient Story

Patient Info: Anne, Female, 50s | Stage II

As of 2023, Anne was receiving/continuing care for Stage II breast cancer after lumpectomy, paclitaxel chemotherapy, radiation therapy, and a targeted-therapy plan reduced to 9 rounds by insurance coverage.

Our Cancer Stories
OutcomeCare Ongoing
Diana, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Diana's Patient Story

Patient Info: Diana, Female, 40s | Stage III

As of 2023, Diana was receiving treatment for Stage III breast cancer after quadrantectomy, chemotherapy, radiation therapy, hormone therapy, unilateral oncological mammoplasty, and lymph-node removal.

Our Cancer Stories
OutcomeCare Ongoing